AstraZeneca CEO Heralds New Era of Collaboration
The Cambridge Independent website reported that AstraZeneca CEO Pascal Soriot announced that the company’s advanced drug discovery robot, NiCoLA-B, will be housed in the biopharmaceutical company’s new £500million global research and development center, heralding a new era of openness and collaboration between life science researchers. “Our Open Innovation platform lets our partners, such as Cancer Research UK and the Medical Research Council, collaborate with us in our use of NiCoLA-B,” Soriot said. “We want to collaborate, operate in a porous environment where ideas can be shared. Our new R&D site at the Cambridge Biomedical Campus will minimize security – pharma companies are historically very secretive and have tight security – and we have designed our building so it is open to the external world, invites others to visit us and supports the creation of this porous environment,” he added.
Click here to read the full article.